Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors – Markets Insider
Weekly Register |
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
Markets Insider As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … Financial Comparison: Editas Medicine (EDIT) and PAREXEL International (PRXL) Financial Newsletter – Zacks SEC FORM 4 – SEC.gov |
